Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Ishikawa, Japan.
Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan.
Hum Pathol. 2018 Jul;77:130-138. doi: 10.1016/j.humpath.2018.04.001. Epub 2018 Apr 21.
Multicentric Castleman disease (MCD) is a systemic inflammatory disease potentially caused by an increase in the serum interleukin-6 (IL-6) level. Idiopathic MCD (iMCD) is histopathologically classified into three types: plasmacytic (PC), mixed, and hypervascular (hyperV) types. Recently, a unique clinical phenotype with a poor prognosis overlap with iMCD, thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly (TAFRO syndrome), has been reported from Japan, but its detailed clinicopathological features remain unclear. In this study, we performed a clinicopathological analysis of 70 nodal cases of iMCD with and without TAFRO syndrome (n = 37 versus n = 33). Compared with iMCD without TAFRO, iMCD with TAFRO showed more atrophic lymphoid follicles (LF), greater distances between follicles, increased glomeruloid vascular proliferation within the germinal center, and increased follicular dendritic cells. In addition, the hyperV type in particular demonstrated severe atrophic LF and interfollicular vascular proliferation. Among the mixed-type cases, the serum IL-6 levels in iMCD with TAFRO were significantly higher than those in iMCD without TAFRO. Furthermore, compared to iMCD without TAFRO, the numbers of immunoglobulin G4 (IgG4)-positive and CD38-positive plasma cells were significantly decreased in iMCD with TAFRO.
多中心 Castleman 病(MCD)是一种全身性炎症性疾病,可能由血清白细胞介素 6(IL-6)水平升高引起。特发性 MCD(iMCD)在组织病理学上分为 3 种类型:浆细胞型(PC)、混合性和高血管型(hyperV)。最近,日本报道了一种独特的临床表现,其预后较差,与 iMCD、血小板减少症、全身性水肿、发热、肾衰竭或网状纤维形成和器官肿大(TAFRO 综合征)重叠,但其详细的临床病理特征仍不清楚。在这项研究中,我们对伴有和不伴有 TAFRO 综合征的 70 例淋巴结 iMCD 病例(n=37 与 n=33)进行了临床病理分析。与不伴有 TAFRO 的 iMCD 相比,伴有 TAFRO 的 iMCD 显示出更多的淋巴滤泡萎缩(LF),滤泡之间的距离更大,生发中心内的血管增生呈肾小球样,滤泡树突状细胞增多。此外,高血管型尤其表现出严重的 LF 萎缩和滤泡间血管增生。在混合性病例中,伴有 TAFRO 的 iMCD 血清 IL-6 水平明显高于不伴有 TAFRO 的 iMCD。此外,与不伴有 TAFRO 的 iMCD 相比,伴有 TAFRO 的 iMCD 中 IgG4 阳性和 CD38 阳性浆细胞的数量明显减少。